Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Accumulated Expenses (2024 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Other Accumulated Expenses for 2 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 335.74% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, up 335.74% year-over-year, with the annual reading at $2.8 million for FY2025, 335.74% up from the prior year.
  • Other Accumulated Expenses hit $2.8 million in Q4 2025 for Insight Molecular Diagnostics, up from $638000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $2.8 million in Q4 2025 to a low of $638000.0 in Q4 2024.